#KRAS 🎯cancer patient group for reliable Knowledge Research Advocacy & Survivorship. Survival of the strategic. #KickCancersKRAS - 🚫 #KRASholes
International, ALL RAS cancers
Joined February 2020
- Tweets5K
- Following4.9K
- Followers4.2K
- Likes12.4K
Pinned Tweet
At @ASCO #GI26 we presented our KRAS KICKERS Trial Finder.
Personalized: KRAS G12D, CRC, US trials
Results (in 4 minutes): 20 trials
go to KRASHUB.ORG
in beta - would love your feedback
abstract
asco.org/abstracts-presentat…
FYI:
G12V - 8 trials for CRC
G12R - 7 trials for CRC
#ESMO26 790RO: QTX3034, oral #G12D #KRAS inh, plus Cetuximab ± mFOLFOX6 in MSS #CRC after oxaliplatin- and irinotecan-based chemo.
ORR 26%, DCR 79%, dose reduction 14%, discontinuation 3%. Expected GI AEs and acneiform rash (combination).
#ColonCancer @myESMO @OncoAlert
🆙 #ESMO26 Rapid Oral 2: #LCSM Mets
🔥Calderasib (MK-1084), Alone or in Combination, for KRAS G12C-Mutant Metastatic Non-Small Cell Lung Cancer
🎙️ @nahit_sendur
🔢2680RO
☑️NCT05067283
🔗 cslide.ctimeetingtech.com/es…
@OncoAlert @Larvol @myESMO @IASLC @KRASKickers
#ESMO26 790RO: QTX3034, oral #G12D #KRAS inh, plus Cetuximab ± mFOLFOX6 in MSS #CRC after oxaliplatin- and irinotecan-based chemo.
ORR 26%, DCR 79%, dose reduction 14%, discontinuation 3%. Expected GI AEs and acneiform rash (combination).
#ColonCancer @myESMO @OncoAlert
KRAS Kickers retweeted
My picks for #CRC and #PDAC sessions at #ESMO26 Madrid. Some interesting posters as well. Full abstracts will be released soon. Looking forward to meeting with colleagues and discussing these data.
@myESMO #colorectal #pancreas #colon #rectum @OncoAlert
One of my most anticipated #ESMO26 presentations:
Krascendo 1 (LBA5) — phase III divarasib vs sotorasib/adagrasib in previously treated KRAS G12C+ NSCLC.
Roche reports positive PFS and interim OS results.
But the effect sizes and full safety data are still pending.
KRAS Kickers retweeted
This year, we celebrated a group of outstanding PanCAN volunteers who exemplify leadership, service, community-building and commitment to our mission. We’re proud to share the recipients of our inaugural PanCAN National Volunteer Awards.
Congratulations to Steve M., Community Chair for our New Jersey Affiliate, on receiving the Randy Pausch Award! 📣
Please join us in congratulating #PanCANvolunteer Steve in the comments and celebrating his dedication to the PanCAN community! 💜
Expansion: from 294 to 344 patients
new arm for Colorectal Cancer Patients:
Part B1 w JAB-23E73 combined with cetuximab
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration - RAS ON/OFF trial
Phase 1/2 trial NCT06973564
Opened May 2025
4 US locations
clinicaltrials.gov/study/NCT…
AACR23:
Preclinical investigation of orally bioavailable, potent KRASmulti inhibitor JAB-23425
aacrjournals.org/cancerres/a…
KRAS Kickers retweeted
We surveyed ⬆️ 300 pts w/ 🫁 ca & 79% have never participated in a #clinicaltrial @cardismith
1) 30% reported not enrolling as they felt it was a last resort/there is an FDA approved option
2) 79% were never offered
We need better CT education for staff and pts!Time to act!
KRAS Kickers retweeted
Young-onset colorectal cancer is rising, and CRC demands focus. @MDAndersonNews has created a dedicated Department of Colorectal Medical Oncology to meet that challenge. Honored to serve as its inaugural Chair and partner with new GI Med Onc chair Arvind Dasari @adasarimd #CRCSM
KRAS Kickers retweeted
🌤️ The pancreatic cancer story is changing. RAS inhibitors are opening one front. Precision IO may be opening another. @ASCO 2026 we presented promising early 1L mPDAC data with CLDN18.2/CD47 bispecific spevatamig (PT886): ORR 52%, DCR 90.5%, mOS 14.7 months. ✨For the 1st time in decades, it feels like the code of this lethal disease is finally breaking✨.
@UPMCHillmanCC @OncoAlert @OncUpdates @OncBrothers – at Chicago, IL
KRAS Kickers retweeted
📺 @AnwaarSaeed3 spoke with @MaenAbdelrahim of on the early efficacy data of #spevatamig, an IgG1-based bispecific antibody, combined with #gemcitabine and nab-paclitaxel for the treatment of metastatic #pancreatic cancer: buff.ly/BVYy97r
KRAS Kickers retweeted
5 Pancreatic Cancer Trials to Watch at ESMO 2026
The ESMO Congress 2026 will feature new pancreatic cancer data across resected, borderline resectable, locally advanced, and metastatic disease.
Trials to watch:
• RASolute 302 — Additional subgroup analyses of daraxonrasib vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma
• AMPLIFY-7P — Randomized phase II results with ELI-002 7P vs observation in resected pancreatic ductal adenocarcinoma
• MASTERPLAN — mFOLFIRINOX with or without SBRT in patients with high-risk, borderline resectable, or locally advanced pancreatic cancer
• HRS-4642 — Preliminary phase II results with HRS-4642 + chemotherapy ± adebrelimab as perioperative therapy in KRAS G12D-mutant pancreatic cancer
• INCB161734 — Safety and efficacy of INCB161734 in combination with chemotherapy in advanced or metastatic pancreatic ductal adenocarcinoma
Together, these five presentations will provide additional data across resected, locally advanced, and metastatic pancreatic cancer, including several RAS-directed treatment strategies.
@AHollebecque @WainbergZev @EileenMOReilly
📎oncodaily.com/gastrointestin…
#ESMO2026 #KRAS #OncoDaily
" In patients with RAS G12-mutated tumors and ECOG PS 0-1, daraxonrasib is recommended after failure of chemotherapy."
🚨 ESMO Updates Metastatic Pancreatic Cancer Guidance With Daraxonrasib
On August 19, ESMO published an Express Update on metastatic pancreatic cancer, with new recommendations on molecular profiling and second-line treatment following recent efficacy data for daraxonrasib.
Key points:
🔹 Molecular profiling is recommended at diagnosis for all patients with unresectable PDAC.
🔹 In patients with RAS G12-mutated tumors and ECOG PS 0-1, daraxonrasib is recommended after failure of chemotherapy.
🔹 In RASolute 302, median OS was 13.2 months with daraxonrasib vs 6.6 months with chemotherapy (HR 0.40).
🔹 In the RAS G12-mutated population, median PFS was 7.3 months with daraxonrasib vs 3.5 months with chemotherapy (HR 0.45).
Daraxonrasib is currently under FDA and EMA regulatory review and is not yet approved.
@MichelDucreux @myESMO @RevMedicines
👉oncodaily.com/oncolibrary/ga…
#PDAC #OncoDaily
"The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion of RASONQUE (daraxonrasib) once-daily oral tablets as a monotherapy indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. If approved by the European Commission (EC), RASONQUE would provide the first broad RAS-targeted treatment option in the European Union for adults with metastatic pancreatic adenocarcinoma."
"Once granted by the EC, the centralized marketing authorization will be valid in all EU member states, as well as in the European Economic Area (EEA) countries Iceland, Norway and Liechtenstein; marketing authorization by the EC is not applicable in the United Kingdom or Switzerland, which have separate processes for considering new drug applications."
The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for our multi-selective RAS(ON) inhibitor for adults with metastatic pancreatic cancer in the EU.
Read more: revmed.com/media/news/13621/…
#ForMediaOnly
EXPANSION from 145 from to 545 patients
Expansion to 13 arms including those
with "previously treated KRAS-mutant mCRC." and
"Dose expansion cohorts will be evaluated to further investigate KST-605 as monotherapy in prior RAS/KRAS inhibitor-treated solid tumors."
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
TRIAL CHANGES (screenshot)
clinicaltrials.gov/study/NCT…
FDA Fast Track Designation - September 2026
@OncLive
onclive.com/view/fda-grants-…
KRAS Kickers retweeted
Early data on VS-7375, @VerastemOncolog KRASG12D inhibitor in 2nd line and beyond #PancreaticCancer
50% ORR in 2nd line, 35% in 3rd/4th line
6mo OS of 80%
Proceeding with Phase 3 randomized trial in 1st line pancreatic (VS-7375 +EGFRi v VS-7375 + chemo)
investor.verastem.com/news-r…
KRAS Kickers retweeted
Early KRAS G12D data in pancreatic cancer: VS-7375 achieved a 50% confirmed ORR in second-line mPDAC (4/8 patients).
At 900 mg daily, the investigational oral inhibitor also showed:
• 41% confirmed ORR across 2L+ disease (9/22)
• 67% six-month landmark PFS in that cohort
These are small, non-randomized phase 1/2 cohorts. A first-line phase 3 trial is planned to open by year-end 2026.
oncologynexus.com/vs-7375-sh…
@VerastemOncolog
@DrMhidalgo @hopkinskimmel @nyulangone
KRAS Kickers retweeted
Every Kaplan–Meier curve represents someone’s life.
As we head into #ESMO26, these 10 principles for humanising science reporting are an important reminder that how we communicate cancer research matters as much as what we report.
Beyond hazard ratios, response rates and p-values, we need to ask:
🔹 What does this mean for patients?
🔹 What is the treatment burden?
🔹 Who can actually access this innovation?
🔹 What uncertainties remain?
Good science reporting doesn’t just communicate results. It communicates why they matter.
Excellent guidance from @myESMO. 👏
